Key terms

About VCNX

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest VCNX news

Apr 02 4:13pm ET Vaccinex files to sell 434K shares of common stock for holders by TipRanks Apr 02 8:41am ET Vaccinex reports FY23 EPS ($43.68) vs ($98.05) last year by TipRanks Mar 27 8:36am ET Vaccinex prices 193,000 shares at $7.77 in registered direct offering by TipRanks Feb 22 10:59am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 21 10:22am ET Vaccinex Inc Broadens Reach with ActivMab® Technology Deals by TipRanks Feb 21 8:07am ET Vaccinex enters eight new antibody discovery agreements for use of ActivMAb by TipRanks Feb 16 7:50pm ET Vaccinex trading halted, news pending by TipRanks Feb 15 8:22am ET Vaccinex Inc Announces Reverse Stock Split and Equity Adjustments by TipRanks Feb 15 8:04am ET Vaccinex announces 1-for-14 reverse stock split by TipRanks Feb 13 4:43pm ET Vaccinex Inc Stockholders Approve Reverse Stock Split by TipRanks Feb 08 4:32am ET Vaccinex Clarifies No Intent for Equity Sales by TipRanks Feb 08 4:32am ET Vaccinex Inc Secures $3.7M in Private Placement Deal by TipRanks Feb 07 8:10am ET Vaccinex prices 3.84M shares at 72.5c in private placement by TipRanks Jan 10 5:18pm ET Vaccinex files to sell 712,484 shares of common stock for holders by TipRanks

No recent press releases are available for VCNX

VCNX Financials

1-year income & revenue

Key terms

VCNX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

VCNX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming